AFM
MIST icon

Anson Funds Management’s Milestone Pharmaceuticals MIST Stock Holding History

Anson Funds Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,113
Closed -$336K – 279
2020
Q4 		$336K Buy
+50,113
New +$336K 0.07% 134

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Anson Funds Management's MIST Position: Q1 2021 in Review

Anson Funds Management sold out of Milestone Pharmaceuticals (MIST) in Q1 2021, closing a stake of 50,113 shares — an estimated $336K sold.

Anson Funds Management first reported a position in MIST in Q4 2020 and held it in 1 quarter. The position peaked at $336K in Q4 2020. 34 funds tracked by Wall St. Rank hold MIST as of Q1 2021.

  • Anson Funds Management reported no remaining Milestone Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Anson Funds Management sold 50,113 Milestone Pharmaceuticals shares in Q1 2021, an estimated $336K.
  • Anson Funds Management first reported a position in Milestone Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Anson Funds Management's Milestone Pharmaceuticals position peaked at $336K in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2021.

Based on Anson Funds Management's 13F filing for Q1 2021, filed 14 May 2021.